# Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China

> **NCT05610566** · NA · RECRUITING · sponsor: **Peijia Medical Technology (Suzhou) Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Mitral Regurgitation

## Interventions

- **DEVICE:** the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System

## Key facts

- **NCT ID:** NCT05610566
- **Lead sponsor:** Peijia Medical Technology (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-06
- **Primary completion:** 2025-07-06
- **Final completion:** 2029-07-06
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2022-11-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610566, "Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05610566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*